The FDA has expanded the scope of existing 510(k) exemptions for certain clinical toxicology test systems intended for use in Federal drug testing programmes, subject to specific conditions and limitations.
At a glance
- The measure: a final order that took effect on 6 October 2026.
- The scope: 14 types of Class II clinical toxicology test systems.
- The change: removal of the previous exclusion for devices intended for Federal drug testing programmes.
- The limitation: eligibility depends on intended use, labelling and applicable exemption limitations.
- The distinction: exemption from 510(k) requirements does not remove other applicable regulatory obligations.
What does a 510(k) exemption mean?
A 510(k) is a premarket notification used to demonstrate that a device is substantially equivalent to a legally marketed device, commonly referred to as a predicate.
When this pathway applies, FDA clearance is required before commercial distribution. An exempt device can be marketed without submitting a 510(k), provided it falls within the scope of the exemption and complies with other applicable requirements.
A 510(k) exemption is therefore distinct from an individual FDA clearance: qualifying for an exemption does not mean that the device has undergone that review.
What has changed?
The order covers 14 types of Class II clinical toxicology test systems identified in classification regulations under 21 CFR Part 862.
These include test systems for amphetamine, benzodiazepines, cocaine and its metabolite benzoylecgonine, methadone, opiates and cannabinoids.
Previously, the relevant exemptions covered devices intended for employment and insurance testing but excluded those intended for Federal drug testing programmes. The final order removes this exclusion while retaining the other conditions.
FDA regulates devices used in these programmes, while the Substance Abuse and Mental Health Services Administration (SAMHSA), through its Division of Workplace Programs, oversees Federal drug-free workplace programmes and the National Laboratory Certification Program (NLCP).
The expansion of the 510(k) exemptions therefore does not automatically authorise the use of specific testing methods in Federal programmes, which are governed separately.
Why intended use and labelling matter
The distinction between different uses of a test system is central to determining whether an exemption applies.
For example, the classification regulation for amphetamine test systems distinguishes employment and insurance testing from other uses. The exemption requires the device to be intended solely for those purposes and its labelling to include a statement to that effect.
The FDA has clarified that no specific wording is prescribed for this statement. However, the labelling must comply with applicable requirements and must not be false or misleading.
The substance measured is therefore only one element of the regulatory context. The purpose for which the test is marketed also matters.
Two systems measuring the same substance may consequently have different exemption statuses because of their intended uses or other characteristics.
The general limitations still apply
21 CFR 862.9 establishes general limitations on 510(k) exemptions for this device category.
A 510(k) remains necessary, for example, when a device has a different intended use from a legally marketed device within the same generic type or operates using a different fundamental scientific technology.
The provision also includes specific limitations for in vitro diagnostic devices (IVDs), including point-of-care testing.
Eligibility for an exemption therefore depends on the individual device, its intended use and the technology employed. Classification within a generic device type does not automatically establish eligibility.
Which obligations remain?
A 510(k) exemption is not a general exemption from FDA regulation.
The FDA explains that exempt devices remain subject to other applicable regulatory controls unless specifically exempted.
In particular, a 510(k) exemption does not automatically provide an exemption from the applicable requirements of the Quality Management System Regulation (QMSR), 21 CFR Part 820, which took effect in its amended form on 2 February 2026.
Depending on the applicable provisions, continuing obligations include establishment registration, device listing, labelling and medical device reporting requirements.
Class II devices also remain subject to the relevant general and special controls.
Why this development matters
The measure illustrates the relationship between device classification, intended use and the conditions attached to a regulatory exemption.
The applicable classification regulation, product code, labelling requirements and both general and partial limitations determine whether the exemption applies. FDA resources, including the Product Classification database and decisions published in the Federal Register, describe these distinctions.
The order is expected to reduce the burden associated with premarket notification for test systems that meet the exemption conditions, while other applicable regulatory requirements remain in place.
The practical impact of this targeted change to the premarket pathway depends on each device’s characteristics and intended use.
Official sources
- Federal Register — Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems
- FDA — Premarket Notification 510(k)
- FDA — Class I and Class II Device Exemptions
- eCFR — 21 CFR 862.9: Limitations of exemptions
- FDA — Quality Management System Regulation (QMSR)
- FDA — Regulatory Controls
Stay informed with MDN – Medical Device News
MDN is a free weekly newsletter dedicated to regulatory updates on medical devices and IVDs, based on official and institutional sources.
Subscribers receive it by email every Monday, one week before publication on the website.
Subscribe to MDN – Medical Device News.
Did you find this insight useful?
If you found this insight useful, you can share it with other professionals in the sector.
More articles
Informational note
This article is for informational purposes only and does not constitute regulatory, legal, technical or professional advice. For applicable requirements and procedures, please refer to the official texts and current documentation issued by the competent authorities.